Recombinant Human Endostatin Injection Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors by Continuous Intravenous Pumping
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2017
Price : $35 *
At a glance
- Drugs Endostatin (Primary)
- Indications Neurofibromatoses; Neurofibromatosis 2
- Focus Therapeutic Use
- 14 Feb 2017 Last checked against ClinicalTrials.gov record.
- 14 Apr 2016 Status changed from active, no longer recruiting to completed.
- 11 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Mar 2016, as reported by ClinicalTrials.gov.